title: Inhibition of Ca(2+)-sensitive K+ currents in NG 108-15 cells by substance P and related tachykinins.
abstract: 1. The whole-cell patch-clamp technique was used to investigate the actions of substance P and other agonists at neurokinin (NK) receptors on voltage-gated K+ and Ca+ channel currents in undifferentiated mouse neuroblastoma x rat glioma NG 108-15 cells. 2. Both substance P (0.3-30 microM) and the NK1 receptor selective agonist GR73632 (10 nM-10 microM) caused concentration-dependent inhibition of K+ currents. GR64349 and senktide (agonists at NK2 and NK3 receptors respectively) also inhibited K+ currents, but only at concentrations which were several orders of magnitude greater than GR73632, suggesting that current inhibition was mediated via NK1 receptors. 3. Substance P and GR73632 were without effect on residual K+ currents recorded in the presence of extracellular Co2+ (4 mM) to abolish the Ca(2+)-sensitive component (IKca) of the K+ current. Ca2+ channel currents, recorded with either Ba2+ or Ca2+ as charge carrier, were unaffected by NK1, NK2 and NK3 receptor ligands. 4. Iontophoretic application of GR73632 produced a current-dependent reduction of K+ currents. In the presence of the non-peptide NK1 antagonists, CP-99,994 and RP67580, and the peptide antagonist, GR82334, the current-response relationship was reversibly shifted to the right. This indicates that the response is mediated by NK1 receptors. 5. Our results indicate that activation of NK1 receptors leads to the selective inhibition of IKca in undifferentiated NG 108-15 cells.
authors.affiliation: Department of Pharmacology, University of Leeds.
authors.forename: S
authors.initials: S
authors.lastname: Phenna
authors.forename: E
authors.initials: E
authors.lastname: Carpenter
authors.forename: C
authors.initials: C
authors.lastname: Peers
authors.forename: S
authors.initials: S
authors.lastname: Maudsley
authors.forename: J P
authors.initials: JP
authors.lastname: Gent
mesh_terms: D000818:Animals; D002118:Calcium / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D004347:Drug Interactions; D005910:Glioma / Q000378:metabolism; D007700:Kinetics; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000502:physiology; D051381:Rats; D018040:Receptors, Neurokinin-1 / Q000819:agonists / Q000502:physiology; D012680:Sensitivity and Specificity; D013373:Substance P / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D015320:Tachykinins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D015220:Calcium Channels; D010446:Peptide Fragments; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D018040:Receptors, Neurokinin-1; D015320:Tachykinins; C068032:GR 73632; D013373:Substance P; D011188:Potassium; D002118:Calcium